Upstream Bio, Inc. (NASDAQ:UPB) Receives $45.25 Consensus Target Price from Analysts

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have been given an average rating of “Moderate Buy” by the five analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $45.25.

Several analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, October 8th. Lifesci Capital started coverage on Upstream Bio in a report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price target on the stock. Evercore ISI began coverage on Upstream Bio in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $40.00 price objective for the company. Mizuho upgraded shares of Upstream Bio to a “strong-buy” rating in a research note on Thursday, December 18th. Finally, Truist Financial began coverage on shares of Upstream Bio in a report on Tuesday, October 14th. They issued a “buy” rating and a $47.00 target price on the stock.

Upstream Bio Stock Performance

NASDAQ UPB opened at $32.30 on Monday. The firm has a 50 day simple moving average of $27.51 and a 200-day simple moving average of $20.80. Upstream Bio has a one year low of $5.14 and a one year high of $33.68. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -17.18 and a beta of 1.90.

Upstream Bio (NASDAQ:UPB) last announced its earnings results on Wednesday, November 5th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.15. Upstream Bio had a negative net margin of 4,366.77% and a negative return on equity of 28.71%. The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.65 million. Equities analysts predict that Upstream Bio will post -4.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Upstream Bio

Several large investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in Upstream Bio during the 4th quarter worth $150,000. JPMorgan Chase & Co. grew its holdings in shares of Upstream Bio by 81.8% during the third quarter. JPMorgan Chase & Co. now owns 29,947 shares of the company’s stock worth $563,000 after purchasing an additional 13,478 shares during the last quarter. Woodline Partners LP grew its holdings in shares of Upstream Bio by 7.9% during the third quarter. Woodline Partners LP now owns 602,252 shares of the company’s stock worth $11,328,000 after purchasing an additional 44,000 shares during the last quarter. Verition Fund Management LLC increased its position in shares of Upstream Bio by 40.3% during the third quarter. Verition Fund Management LLC now owns 47,001 shares of the company’s stock worth $884,000 after purchasing an additional 13,496 shares in the last quarter. Finally, Prelude Capital Management LLC acquired a new stake in shares of Upstream Bio in the 3rd quarter valued at about $296,000.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.